Trial Profile
Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Rotavirus vaccine (Primary) ; Rotavirus vaccine
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 28 Jan 2020 Status changed from active, no longer recruiting to completed.
- 18 Nov 2019 Planned End Date changed from 2 Feb 2020 to 3 Feb 2020.
- 18 Nov 2019 Status changed from recruiting to active, no longer recruiting.